SB-699551

SB-699551 is a drug which was the first compound developed to act as a selective antagonist for the serotonin receptor 5-HT_5A, with selectivity of around 100x over other serotonin receptor subtypes.^[1] Multiple therapeutic roles have been suggested for 5-HT_5A ligands due to the presence of this receptor in several areas of the brain, but research is still at an early stage,^[2] In animal studies, SB-699551 was found to block cue-mediated responding to LSD, again suggesting an antipsychotic type of activity.^[3] It also reduces the viability of certain types of cancer cells in vitro, suggesting the 5-HT_5A receptor as a possible target for novel chemotherapy drugs.^[4][5]

SB-699551

Identifiers
IUPAC name 3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-([(2-phenylethyl)amino]methyl)-4-biphenylyl)methyl]propanamide
CAS Number	791789-61-2 Y
PubChem CID	11168182
ChemSpider	9343277
UNII	3FN59X9DPR
CompTox Dashboard (EPA)	DTXSID90457468
Chemical and physical data
Formula	C34H45N3O
Molar mass	511.754 g·mol−1
3D model (JSmol)	Interactive image
SMILES C2CCCC2CCC(=O)N(CCN(C)C)Cc(cc3)ccc3-c(cc1)ccc1CNCCc4ccccc4
InChI InChI=1S/C34H45N3O/c1-36(2)24-25-37(34(38)21-16-28-10-6-7-11-28)27-31-14-19-33(20-15-31)32-17-12-30(13-18-32)26-35-23-22-29-8-4-3-5-9-29/h3-5,8-9,12-15,17-20,28,35H,6-7,10-11,16,21-27H2,1-2H3 Key:SEQAMPXQRKYYQF-UHFFFAOYSA-N
(verify)